Recent pages

Company Name

Z/ZymoGenetics (ZGEN)

Edit
page

New
page

Print
page

This page was last modified over a year ago by Sysop

ZymoGenetics (ZGEN)

This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below.

From 1

1. Company Information:
2. Company Overview:

2.1. Company Products/Services/Markets:
2.2. Strategy:
2.3. Competitors:
2.4. Industry Trends and News:
2.5. Acquisitions, Divestitures, Major Transactions, Spin-offs :
2.6. Management – Pros & Cons, Changes:

5.1. Buy Rationale:
5.2. Sell Rationale:

6. Projected Financials:
7. Discussion:
8. Footnotes:
9. News:
10. See Also (links to blogs, forums, external sources, etc...):

Company Information:

Company Address:

1201 Eastlake Avenue East

Seattle, WA 98102

Company’s Web Address: http://www.zymogenetics.com/

Industry Sector:

Fiscal Year:

Dividend:

Note: this section is not editable. Please click here to report any inaccuracies.

Shares Outstanding: 67,600,000
Market Capitalization: Updating...

Income Statements
Click for: Annual Income Statement
Click for: Quarterly Income Statement

Balance Sheets
Click for: Annual Balance Sheet
Click for: Quarterly Balance Sheet

Cash Flow Statements
Click for: Annual Cash Flow Statement
Click for: Quarterly Cash Flow Statement

SEC Filings
Click for: Form 10-Ks
Click for: Form 10-Qs
Click for: Annual Proxy Statements
Link to SEC filings search: http://www.sec.gov/cgi-bin/srch-edgar

Company Overview:

Note: this section is not editable.

ZymoGenetics, Inc. (ZGEN) was formed in 1981 and was acquired in 1988 by Novo Nordisk, one of the world's largest producers of therapeutic proteins, for 12 years. However, it became an independent pharmaceutical company after it was spun off from Novo Nordisk in 2000. The company completed an initial public offering in February, 2002. Since its inception in 1981, the company s focus on therapeutic proteins has allowed it to enter into collaboration agreements with other pharmaceutical companies like Johnson & Johnson, Novo Nordisk, and Eisai Co., Ltd. ZymoGenetics allowed these companies to market therapeutic proteins, which help earn royalties on product sales. ZymoGenetics has contributed to the discovery or development of six recombinant protein products currently being marketed by its collaborators. The company has also entered into an option and license agreement with Novo Nordisk, which allows it to earn revenue in the form of license fees and milestone payments.

An important element of ZymoGenetics' strategy is that the company intends to maintain all or a significant share of the commercial rights to a number of its product candidates in North American markets. As a result, the company will be required to pay a significant portion of the development costs for these product candidates.

ZymoGenetics employs over 500 employees and is headquartered in Seattle, WA.

Read full report on ZymoGenetics

Company overview provided by

Company Products/Services/Markets:

Enter Company Products/Services Here

Strategy:

Describe Key Aspects of Company's Strategy Here

Competitors:

Enter Competitors Here

Industry Trends and News:

Enter Industry Trends and News Here

Acquisitions, Divestitures, Major Transactions, Spin-offs :

Enter Acquisitions, Divestiures, Major Transactions, Spin-offs Here

Management – Pros & Cons, Changes:

Enter Management - Pros & Cons, Changes Here

Financial Analysis:

Enter Financial Analysis Here

Valuation:

Enter Valuation Analysis and Valuation Ratios Here

	2007	2006	2005
Price/Earnings
Price/EBITDA
Price/Pre-tax Income
Price/Revenue

Investment Rationale:

Buy Rationale:

Enter Buy Rationale Here

Sell Rationale:

Enter Sell Rationale Here

Projected Financials:

Income Statement: (Paste Here)

Balance Sheet: (Paste Here)

Cash Flow Statement: (Paste Here)

Financial Ratios: (Paste Here)

Other: (Paste Here)

Discussion:

This area is for debates regarding different recommendations for this stock.

Footnotes:

News:

Yahoo! Finance Blog
Add this Facebook Y! application to your profile In a tough market, I get by with a little help from my friends… The turbulence and wild swings of the world’s financial markets have been enough to make even the sturdiest of investors a little queasy as of late. If you haven’t already, you will likely lose most of your appetite for risk as [...]
Yahoo! Finance Goes Global At midnight on Tuesday, something great happened. Something BRILLIANT. Yahoo! Finance launched 15 new pages across Europe to some great user feedback. But it wasn’t just the pages that we should be rightly proud of –- it’s the united Global Yahoo! Finance team behind it; the upgraded processes and infrastructure behind the design. Engineers, [...]
Introducing Ticker Tape on the Quotes Pages We are excited to add a popular new feature to the top of all our quotes pages. Now you have faster and easier access to stocks you care most about. The new ticker tape, prominently placed, displays the most recent quotes you last looked at. This is the same useful functionality we offer [...]
Getting the most out of the Interactive Chart If you’ve clicked the thumbnail chart — or a time period link below it — on our quote page, you’ve likely visited our Interactive Chart. The Interactive Chart is a relatively new addition to Yahoo! Finance; it became generally available in April. There are several things you can do on the Interactive Chart that you [...]
Real-Time ECN Quotes Are Now Available on Multi-Quote and Portfolios Pages! Thanks to everyone for the great feedback on our recent real-time features on Yahoo! Finance. We know this is information you value, so today we’re pleased to build on our real-time features with the addition of Real-Time ECN views in multi-quote and portfolio pages on Yahoo! Finance. With the markets being volatile and earnings right around [...]